Literature DB >> 23356980

Targeting cell cycle regulation in cancer therapy.

Santiago Diaz-Moralli1, Míriam Tarrado-Castellarnau, Anibal Miranda, Marta Cascante.   

Abstract

Cell proliferation is an essential mechanism for growth, development and regeneration of eukaryotic organisms; however, it is also the cause of one of the most devastating diseases of our era: cancer. Given the relevance of the processes in which cell proliferation is involved, its regulation is of paramount importance for multicellular organisms. Cell division is orchestrated by a complex network of interactions between proteins, metabolism and microenvironment including several signaling pathways and mechanisms of control aiming to enable cell proliferation only in response to specific stimuli and under adequate conditions. Three main players have been identified in the coordinated variation of the many molecules that play a role in cell cycle: i) The cell cycle protein machinery including cyclin-dependent kinases (CDK)-cyclin complexes and related kinases, ii) The metabolic enzymes and related metabolites and iii) The reactive-oxygen species (ROS) and cellular redox status. The role of these key players and the interaction between oscillatory and non-oscillatory species have proved essential for driving the cell cycle. Moreover, cancer development has been associated to defects in all of them. Here, we provide an overview on the role of CDK-cyclin complexes, metabolic adaptations and oxidative stress in regulating progression through each cell cycle phase and transitions between them. Thus, new approaches for the design of innovative cancer therapies targeting crosstalk between cell cycle simultaneous events are proposed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23356980     DOI: 10.1016/j.pharmthera.2013.01.011

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  113 in total

1.  Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells.

Authors:  Anusha Chidambaram; Arunachalam Sekar; Kavya S H; Ramesh Kumar Chidambaram; Kalaiarasi Arunachalam; Senthilkumar G P; Ravikumar Vilwanathan
Journal:  Invest New Drugs       Date:  2017-08-03       Impact factor: 3.850

2.  Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.

Authors:  Míriam Tarrado-Castellarnau; Roldán Cortés; Miriam Zanuy; Josep Tarragó-Celada; Ibrahim H Polat; Richard Hill; Teresa W M Fan; Wolfgang Link; Marta Cascante
Journal:  Pharmacol Res       Date:  2015-11-04       Impact factor: 7.658

3.  Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancer.

Authors:  François Gaascht; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2015-11-17       Impact factor: 5.523

4.  A scalable method for molecular network reconstruction identifies properties of targets and mutations in acute myeloid leukemia.

Authors:  Edison Ong; Anthony Szedlak; Yunyi Kang; Peyton Smith; Nicholas Smith; Madison McBride; Darren Finlay; Kristiina Vuori; James Mason; Edward D Ball; Carlo Piermarocchi; Giovanni Paternostro
Journal:  J Comput Biol       Date:  2015-04       Impact factor: 1.479

5.  Dysregulation of the PI3K/Akt signaling pathway affects cell cycle and apoptosis of side population cells in nasopharyngeal carcinoma.

Authors:  Danwei Zheng; Guangchao Zhu; Shan Liao; Wei Yi; Gengqiu Luo; Junyu He; Zhen Pei; Guiyuan Li; Yanhong Zhou
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

6.  Knockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.

Authors:  Xiangmin Zhang; Dongxu Zhang; Fajun Qu; Yi Hong; Jianwei Cao; Xiuwu Pan; Lin Li; Yi Huang; Hai Huang; Lei Yin; Lu Chen; Jizhong Ren; Zhijun Wang; Danfeng Xu; Xingang Cui
Journal:  Mol Cell Biochem       Date:  2014-08-29       Impact factor: 3.396

7.  Invadopodia-mediated ECM degradation is enhanced in the G1 phase of the cell cycle.

Authors:  Battuya Bayarmagnai; Louisiane Perrin; Kamyar Esmaeili Pourfarhangi; Xavier Graña; Erkan Tüzel; Bojana Gligorijevic
Journal:  J Cell Sci       Date:  2019-10-18       Impact factor: 5.285

8.  Dietary Compound Proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves inhibit angiogenesis and regulate cell cycle of cisplatin-resistant ovarian cancer cells via targeting Akt pathway.

Authors:  Yu Zhang; Shiguo Chen; Chaoyang Wei; Gary O Rankin; Yon Rojanasakul; Ning Ren; Xingqian Ye; Yi Charlie Chen
Journal:  J Funct Foods       Date:  2017-12-22       Impact factor: 4.451

Review 9.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

10.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.